-
2024-519983-42-00
4
2025-02-04
TUBERCULOSIS
-
2024-511575-15-00
5
2025-01-29
Central serous chorioretinopathy
-
2024-512628-12-00
10
2025-01-28
Primary aldosteronism
-
2023-508234-34-00
4
2025-01-27
Crohn's disease
-
2023-510322-32-00
5
2025-01-27
patients with incurable, metastatic/recurrent head and neck squamous c
-
2023-510323-30-00
5
2025-01-24
First-line treatment of recurrent or metastatic PD-L1+ head and neck s
-
2024-513852-13-00
5
2025-01-20
KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
-
2024-511359-16-00
5
2025-01-17
Osteoarthritis
-
2024-514615-10-01
9
2025-01-14
Subarachnoid hemorrhage
-
2023-510109-16-00
4
2025-01-06
Acute Respiratory Distress Syndrome (ARDS) Due to Pneumonia or other I
-
2024-515970-28-00
6
2024-12-20
Dystonic tremor syndrome
-
2024-516937-10-01
5
2024-12-18
Melanoma
-
2023-506028-10-00
7
2024-12-11
Myotonic Dystrophy
-
2023-510150-17-00
4
2024-12-11
Active, refractory systemic lupus erythematosus (SLE), and active, re
-
2023-507489-20-00
6
2024-12-10
Statin-intolerance
-
2024-513092-40-00
6
2024-12-05
Stroke
-
2024-518305-17-01
6
2024-12-02
Fungal infection
-
2023-508902-66-00
4
2024-11-28
relapsed / refractory multiple myeloma
-
2024-514055-15-00
6
2024-11-19
Pulmonary sarcoidosis
-
2024-512338-13-00
3
2024-11-11
Metastatic Castration-Resistant Prostate Cancer
-
2023-508475-36-00
5
2024-10-29
Atherosclerotic Cardiovascular Disease
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2024-516940-24-00
4
2024-10-29
locally advanced urothelial cancer.
-
2024-516427-13-00
6
2024-10-28
Posttraumatic Stress Disorder (PTSD)